| Literature DB >> 33964965 |
An-Ran Zhang1,2,3, Wen-Qiang Shi2, Kun Liu4, Xin-Lou Li5, Ming-Jin Liu3, Wen-Hui Zhang2, Guo-Ping Zhao6, Jin-Jin Chen2, Xiao-Ai Zhang2, Dong Miao2, Wei Ma7, Wei Liu8, Yang Yang9, Li-Qun Fang10.
Abstract
BACKGROUND: The ongoing transmission of the Middle East respiratory syndrome coronavirus (MERS-CoV) in the Middle East and its expansion to other regions are raising concerns of a potential pandemic. An in-depth analysis about both population and molecular epidemiology of this pathogen is needed.Entities:
Keywords: Case fatality rate; MERS-CoV; Middle East respiratory syndrome; Phylogeny; Phylogeographic dynamic; Spatial diffusion
Mesh:
Year: 2021 PMID: 33964965 PMCID: PMC8105704 DOI: 10.1186/s40249-021-00853-0
Source DB: PubMed Journal: Infect Dis Poverty ISSN: 2049-9957 Impact factor: 10.485
Baseline demographic and clinical characteristics of confirmed Middle East respiratory syndrome cases reported between September 2012 and June 2020
| Number (%) of cases | |||||
|---|---|---|---|---|---|
| Total | Saudi Arabia | Korea | United Arab Emirates | Others | |
| Number of confirmed cases | 2450 | 2048 | 186 | 93 | 123 |
| Annual incidence (/107) | 0.45 | 94.34 | 4.71 | 14.07 | 0.023 |
| Female | 751 (30.7) | 626 (30.6) | 75 (40.3) | 20 (21.5) | 30 (24.4) |
| Age, years (median, IQR) | 53 (38–65) | 53 (38–65) | 55 (42–66) | 43 (33–59) | 52 (38–65) |
| Number of case cluster | 150 | 123 | 1 | 11 | 15 |
| Number of deaths (CFR, %) | 802 (32.7) | 718 (35.1) | 35 (18.8) | 15 (16.1) | 34 (27.6) |
| Contact history | |||||
| Animals | 356 (14.5) | 310 (15.1) | 0 | 16 (17.2) | 30 (24.4) |
| Patients | 1097 (44.8) | 820 (40.1) | 184 (98.9) | 47 (50.5) | 46 (37.4) |
| Unknown | 997 (40.7) | 918 (44.8) | 2 (1.1) | 30 (32.3) | 47 (38.2) |
| Occupation | |||||
| Healthcare worker | 335 (13.7) | 265 (12.9) | 30 (16.1) | 26 (28.0) | 14 (11.4) |
| Others | 2115 (86.3) | 1783 (87.1) | 156 (83.9) | 67 (72.0) | 109 (88.6) |
| Exposure site | |||||
| Hospital | 724 (29.6) | 496 (24.2) | 185 (99.5) | 21 (22.6) | 22 (17.9) |
| Household | 120 (4.9) | 93 (4.5) | 0 | 11 (11.8) | 16 (13.0) |
| Others | 1606 (65.5) | 1459 (71.3) | 1 (0.5) | 61 (65.6) | 85 (69.1) |
| Asymptomatic infection | 201 (8.2) | 173 (8.5) | 0 | 19 (20.4) | 9 (7.3) |
| Underlying condition | 1272 (51.9) | 1156 (56.5) | 20 (10.8) | 38 (40.9) | 58 (47.2) |
| Time from disease onset to diagnosis, days (median, IQR) | 5 (3–8) | 5 (3–8) | 4 (2–8) | 8 (6–14) | 8 (5–13.5) |
| Time from disease onset to death, days (median, IQR) | 11 (7–17) | 10 (6–16) | 12 (9–16) | 21.5 (18–27) | 16 (11–20) |
| Year of occurrence | |||||
| 2012 | 9 (0.4) | 5 (0.2) | 0 | 0 | 4 (3.3) |
| 2013 | 169 (6.9) | 137 (6.7) | 0 | 12 (12.9) | 20 (16.3) |
| 2014 | 652 (26.6) | 560 (27.3) | 0 | 59 (63.3) | 33 (26.8) |
| 2015 | 680 (27.8) | 457 (22.3) | 185 (99.5) | 7 (7.5) | 31 (25.2) |
| 2016 | 254 (10.4) | 242 (11.8) | 0 | 3 (3.2) | 9 (7.3) |
| 2017 | 250 (10.2) | 237 (11.6) | 0 | 7 (7.5) | 6 (4.9) |
| 2018 | 150 (6.1) | 145 (7.1) | 1 (0.5) | 1 (1.2) | 3 (2.4) |
| 2019 | 226 (9.2) | 208 (10.2) | 0 | 2 (2.2) | 16 (13.0) |
| 2020 | 60 (2.4) | 57 (2.8) | 0 | 2 (2.2) | 1 (0.8) |
IQR, interquartile range; CFR, case fatality rate
Fig. 1Distribution of human MERS cases in the world a, in the Middle East b and in Europe c during 2012–2020. Countries were colored according to the dominant transmission type: (i) zoonotic transmission plus human-to-human transmission, (ii) zoonotic transmission without human-to-human transmission, (iii) imported infection plus human-to-human transmission, and (iv) imported infection without human-to-human transmission.
Logistic regression analyses of potential risk factors for mortality among Middle East respiratory syndrome cases, September 2012–June 2020
| Outcome ( | Univariable | Multivariable | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Death/Total | CFR (95% | 95% | Adjusted | 95% | |||||
| Age group | ≥ 65 years | 392/654 | 59.9 (58.0–61.9) | 5.06 | 4.18–6.12 | < 0.001 | 10.52 | 6.46–17.11 | < 0.001 |
| < 65 years | 410/1796 | 22.8 (21.2–24.5) | 1.00 | – | – | 1.00 | – | – | |
| Sex | Male | 604/1699 | 35.6 (33.7–37.5) | 1.54 | 1.27–1.86 | < 0.001 | 2.34 | 1.57–3.49 | < 0.001 |
| Female | 198/751 | 26.4 (24.6–28.1) | 1.00 | - | -– | 1.00 | – | – | |
| Region | Middle East | 761/2236 | 34.0 (32.1–36.0) | 2.18 | 1.53–3.09 | < 0.001 | 3.09 | 1.97–4.84 | < 0.001 |
| Other | 41/214 | 19.2 (13.9–24.4) | 1.00 | – | – | 1.00 | – | – | |
| Healthcare worker | Yes | 22/335 | 6.6 (3.9–9.2) | 0.12 | 0.08–0.19 | < 0.001 | 0.33 | 0.21–0.54 | < 0.001 |
| No | 780/2115 | 36.9 (34.8–38.9) | 1.00 | – | – | 1.00 | – | – | |
| Underlying condition | Yes | 587/1272 | 46.2 (43.4–48.9) | 6.29 | 4.62–8.55 | < 0.001 | 3.50 | 2.50–4.89 | < 0.001 |
| No | 53/442 | 12.0 (9.0–15.0) | 1.00 | – | – | 1.00 | – | – | |
| Unknown | 162/736 | 22.0 (19.0–25.0) | 2.07 | 1.48–2.90 | < 0.001 | 1.92 | 1.31–2.81 | 0.001 | |
| Animal Contact | Yes | 125/356 | 35.1 (30.2–40.1) | 1.68 | 1.30–2.18 | < 0.001 | 2.97 | 1.10–7.98 | 0.031 |
| No | 267/1097 | 24.3 (21.8–26.9) | 1.00 | – | – | 1.00 | – | – | |
| Unknown | 410/997 | 41.1 (38.1–44.2) | 2.17 | 1.80–2.62 | < 0.001 | 2.41 | 1.54–3.77 | < 0.001 | |
| OTC§ | > 5 days | 331/679 | 48.8 (45.0–52.5) | 1.34 | 1.11–1.62 | 0.003 | 1.31 | 1.05–1.63 | 0.019 |
| ≤ 5 days | 289/773 | 37.4 (34.0–40.8) | 1.00 | – | – | 1.00 | – | – | |
| Year | 2012–2014 | 256/830 | 30.8 (27.7–34.0) | 1.00 | – | – | 1.00 | – | – |
| 2015–2016 | 353/934 | 37.8 (34.7–40.9) | 1.36 | 1.12–1.66 | 0.002 | 1.63 | 1.27–2.09 | < 0.001 | |
| 2017–2019 | 193/686 | 28.1 (24.8–31.5) | 0.88 | 0.70–1.10 | 0.25 | 0.70 | 0.53–0.92 | 0.010 | |
| Age group * Sex | 0.54 | 0.33–0.87 | 0.012 | ||||||
| Age group * Animal contact (with vs without) | 0.29 | 0.16–0.53 | < 0.001 | ||||||
| Age group * Animal contact (unknown vs without) | 0.45 | 0.28–0.72 | 0.001 | ||||||
| Sex * Animal contact (with vs without) | 0.36 | 0.13–0.97 | 0.043 | ||||||
| Sex * Animal contact (unknown vs without) | 0.58 | 0.36–0.94 | 0.028 | ||||||
CFR case fatality rate, OR odds ratio, CI confidence Interval, OTC Time from disease onset to confirmation
§OTC have missing values. Description (column 2–5) are based on non-missing values. But logistic analysis were based on data after interpolation
*Means that there must be no corresponding results for being the control groups
Fig. 2Geographic expansion of MERS a and its relationship with transportation network and land cover b in the Middle East. The first invasion time of each space unit was defined as the time lag between the first confirmed case for each unit and September 20, 2012, the symptom onset date of the first confirmed case in the Middle East Region. The time between adjacent contours was fixed at 200 days, and a wide gap between adjacent contours indicates a faster spatial diffusion of the disease. The inset map in panel a was added to present the early onset situation in the whole Middle East during the first 400 days.
Survival analyses on the time to the first reported Middle East respiratory syndrome case in each space unit, September 2012–June 2020
| Predictors | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% | Hazard ratio | 95% | |||
| Population density(10/km2) | 1.00 | 0.99–1.00 | 0.44 | |||
| Camel density (10/km2) | 1.74 | 1.35–2.23 | < 0.001 | |||
| Elevation (km) | 0.99 | 0.66–1.46 | 0.94 | 2.40 | 1.47–3.91 | < 0.001 |
| Meteorological variable | ||||||
| BIO1 | 1.58 | 1.48–1.68 | < 0.001 | 1.38 | 1.25–1.52 | < 0.001 |
| BIO2 | 1.97 | 1.74–2.23 | < 0.001 | 1.28 | 1.12–1.46 | < 0.001 |
| BIO3 | 1.04 | 1.01–1.07 | 0.012 | |||
| BIO4 | 1.003 | 1.002–1.005 | < 0.001 | |||
| BIO5 | 1.36 | 1.30–1.43 | < 0.001 | |||
| BIO12 | 0.78 | 0.74–0.83 | < 0.001 | |||
| Percentages of land cover (10%) | ||||||
| Cropland | 0.27 | 0.14–0.49 | < 0.001 | 0.51 | 0.27–0.95 | 0.034 |
| Shrubland | 0.20 | 0.07–0.58 | 0.003 | |||
| Bare land | 1.49 | 1.39–1.59 | < 0.001 | 1.13 | 1.03–1.25 | 0.014 |
| Intersect with railway | 3.76 | 2.35–6.01 | < 0.001 | 2.33 | 1.37–3.97 | 0.002 |
| Intersect with main road | 59.53 | 8.27–428.25 | < 0.001 | 15.45 | 2.11–113.26 | 0.007 |
| Number of hospitals (10) | 1.28 | 1.15–1.37 | < 0.001 | 1.19 | 1.04–1.44 | 0.010 |
BIO1 annual average temperature, BIO2 average diurnal range of temperature, BIO3 isothermality, BIO4 temperature seasonality, BIO5 max temperature of warmest month, BIO12 Annual precipitation
Turkey and Iran are excluded in this analysis. Space unit is the third-level administrative area (county) in Saudi Arabia and the second-level administrative area elsewhere
Fig. 3Phylogeny of 489 MERS-CoV whole-genome sequences and potential association of subclades with case fatality. a Time-resolved phylogeny. The colors indicate host states of tree tips or inferred host states of the internal nodes. Case fatality rate b and incidence rate c were associated with the sequences according to their sampling date and location. Movie 1. Spatiotemporal migration dynamics of clade C of MERS-CoV using Nextstrain. https://nextstrain.org/community/wqshi/merse